A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination With Pemetrexed and Cisplatin as Front-line Therapy in Adults With Malignant Pleural Mesothelioma

Trial Profile

A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination With Pemetrexed and Cisplatin as Front-line Therapy in Adults With Malignant Pleural Mesothelioma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs CRS 207 (Primary) ; Cisplatin; Cyclophosphamide; Pemetrexed
  • Indications Mesothelioma
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Aduro BioTech
  • Most Recent Events

    • 25 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
    • 25 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
    • 12 Nov 2016 Positive clinical results from second cohort presented at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC), as per an Aduro Biotech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top